Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
11 Décembre 2023 - 3:00PM
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on
changing the possible for patients through engineered cells, today
announced preclinical data supporting the anti-tumor and immune
evasion capabilities of allogeneic CAR T cells engineered with
Sana’s proprietary hypoimmune (HIP) technology were presented at
the 65th American Society of Hematology (ASH) Annual Meeting in San
Diego, CA.
“These data, indicating that HIP-modified CAR T cells are
consistently able to avoid detection by the immune system while
retaining their functionality and eliciting an anti-tumor effect,
add to our learnings about and the opportunities for our allogeneic
CAR T cell platform,” said Terry Fry, MD, Sana’s Senior Vice
President and Head of T Cell Therapeutics. “HIP-modified allogeneic
CAR T cells remain well-tolerated in preclinical models. We look
forward to initiating several additional clinical studies with our
promising therapeutic candidates, with proof-of-concept data from
multiple trials expected next year, including from SC291, our
CD19-targeted HIP-modified CAR T cell therapy, and SC262. We also
continue to develop our allogeneic CAR T cell pipeline, including
our fully-human GPRC5D-targeted CAR T cell therapy.”
On Sunday, December 10, abstract #3437 titled “Hypoimmune,
Allogeneic CD22-Directed CAR T Cells That Evade Innate and Adaptive
Immune Rejection for the Treatment of Large B Cell Lymphoma
Patients That Are Relapsed/Refractory to CD19-Directed CAR T Cell
Therapy” detailed preclinical data supporting the advancement of
SC262, a CD22-directed HIP CAR T cell therapy, into human clinical
studies. The results demonstrated that CD22 HIP CAR T cells evaded
adaptive immune cell recognition and cytolysis through B2M and
CIITA gene disruption and innate immune cell recognition through
the overexpression of CD47. Furthermore, CD22 HIP CAR T cells
elicited robust tumor control that produced cytokine/effector
analytes and expanded in a dose- and antigen-dependent manner in
vitro, with consistent effect across lots manufactured from
different donors. CD22 HIP CAR T cells were well tolerated with no
signs of graft-versus-host disease (GvHD). Sana submitted the
investigational new drug (IND) application and intends to begin
human testing of SC262 in early 2024.
On Sunday, December 10, abstract #3290 titled “Development of a
Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple
Myeloma Patients” outlined preclinical data demonstrating the
characterization and candidate selection of fully-human
GPRC5D-specific CARs for use in combination with HIP technology to
develop an allogeneic GPRC5D CAR T cell therapy. The data showed
that candidate GPRC5D CARs elicited in vitro cytotoxicity and
effector cytokine production that is comparable to clinically
validated benchmark control CARs. Additionally, these GPRC5D CAR T
cells controlled multiple myeloma tumor cells both in vitro and in
vivo, demonstrating efficacy that is on par with clinical benchmark
GPRC5D CAR T cells.
About Hypoimmune PlatformSana’s hypoimmune
platform is designed to create cells ex vivo that can evade the
patient’s immune system to enable the transplant of allogeneic
cells without the need for immunosuppression. We are applying the
hypoimmune technology to both donor-derived allogeneic T cells,
with the goal of making potent and persistent CAR T cells at scale,
and pluripotent stem cells, which can then be differentiated into
multiple cell types at scale. Preclinical data published in
peer-reviewed journals demonstrate across a variety of cell types
that these transplanted allogeneic cells are able to evade both the
innate and adaptive arms of the immune system while retaining their
activity. Our most advanced programs utilizing this platform
include an allogeneic CAR T program targeting CD19+ cancers,
an allogeneic CAR T program for B-cell mediated autoimmune
diseases, an allogeneic CAR T program targeting CD22+ cancers, and
stem-cell derived pancreatic islet cells for patients with type 1
diabetes.
About Sana BiotechnologySana Biotechnology,
Inc. is focused on creating and delivering engineered cells as
medicines for patients. We share a vision of repairing and
controlling genes, replacing missing or damaged cells, and making
our therapies broadly available to patients. We are a passionate
group of people working together to create an enduring company that
changes how the world treats disease. Sana has operations in
Seattle, Cambridge, South San Francisco, and Rochester. For more
information about Sana Biotechnology, please visit
https://sana.com/.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements about Sana Biotechnology, Inc. (the “Company,” “we,”
“us,” or “our”) within the meaning of the federal securities laws,
including those related to the Company’s vision, progress, and
business plans; expectations for its development programs, product
candidates and technology platforms, including its pre-clinical,
clinical and regulatory development plans and timing expectations,
including with respect to the submission of IND for the SC262
program; the potential significance and impact of preclinical data
regarding the HIP platform; expectations regarding the substance,
timing, and scale of data from the company’s clinical trials; the
ability of HIP-modified CAR T cells to consistently avoid detection
by the immune system while retaining their functionality and
eliciting an anti-tumor effect; the ability to use the HIP platform
to create cells ex vivo that can evade a patient’s immune system
and enable the transplant of allogeneic cells without the need for
immunosuppression and the potential benefits associated therewith;
and the ability to apply the HIP technology to donor-derived
allogeneic T cells to make potent and persistent CAR T cells at
scale and pluripotent stem cells, which can then be differentiated
into multiple cell types at scale. All statements other than
statements of historical facts contained in this press release,
including, among others, statements regarding the Company’s
strategy, expectations, cash runway and future financial condition,
future operations, and prospects, are forward-looking statements.
In some cases, you can identify forward-looking statements by
terminology such as “aim,” “anticipate,” “assume,” “believe,”
“contemplate,” “continue,” “could,” “design,” “due,” “estimate,”
“expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “target,”
“will,” “would” and other similar expressions that are predictions
of or indicate future events and future trends, or the negative of
these terms or other comparable terminology. The Company has based
these forward-looking statements largely on its current
expectations, estimates, forecasts and projections about future
events and financial trends that it believes may affect its
financial condition, results of operations, business strategy and
financial needs. In light of the significant uncertainties in these
forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. These
statements are subject to risks and uncertainties that could cause
the actual results to vary materially, including, among others, the
risks inherent in drug development such as those associated with
the initiation, cost, timing, progress and results of the Company’s
current and future research and development programs, preclinical
and clinical trials. For a detailed discussion of the risk factors
that could affect the Company’s actual results, please refer to the
risk factors identified in the Company’s SEC reports, including but
not limited to its Quarterly Report on Form 10-Q dated November 8,
2023. Except as required by law, the Company undertakes no
obligation to update publicly any forward-looking statements for
any reason.
Investor Relations & Media:Nicole
Keithinvestor.relations@sana.commedia@sana.com
Sana Biotechnology (NASDAQ:SANA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Sana Biotechnology (NASDAQ:SANA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024